Cytokines and Cognitive Decline in Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

133 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Amyloid plaques and neurofibrillary tangles are the 2 well-known etiopathological hallmarks of Alzheimer's disease (AD). Beside these 2 lesions, inflammation response is described in the brain of patients with AD.

The main objective of our study is to analyse the correlation between the value of plasma cytokines (interleukin 1, 6, TNFα and chemochine Rantes) and the rapidity of the cognitive decline in AD over a 2-year follow-up.

Secondary objectives include:

* the predictive value of the cytokines on the cognitive decline after 6 months and one year of follow-up., of the patients include 150 patients with AD (MMSE: 16-25)
* correlation between plasma cytokines levels and expression of the protein kinase PKR (involved in death cell) in blood mononuclear cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

NCT05468073

Alzheimer Disease

RECRUITING PHASE2

Examining Neuroinflammation in AlzHeimer's

NCT03548883

Alzheimer Disease, Early-Onset

COMPLETED

Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease

NCT02800395

Alzheimer Disease

RECRUITING NA

Immunohistochemical Study of Neurodegenerative Diseases

NCT05518409

Alzheimer Disease Lewy Body Disease Neurodegenerative Diseases

UNKNOWN NA

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793

Alzheimer Disease

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood test and cognitive tests

Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Alzheimer's disease (AD)patients
* MMSE score: 16-25
* Written informed consent

Exclusion Criteria

* AD patients with specific treatment for AD before inclusion MMSE score under 16 or over 25 at inclusion
* patients with anti-inflammatory drugs (non steroids or corticosteroids) or immunosuppressive agents
* Patients with acute disease (infectious disease, rheumatologic disease) or chronic disease (malignancy, infectious, rheumatologic disease) that could interact with plasma cytokines level
* Patients with a life threatening disease

Eligible Sex

ALL

Accepts Healthy Volunteers

No